The prevalence of CD found in the present study was 48% (95% confidence interval in parenthesis 37.9-58.2% diagnostic accuracy in children younger than ten years of age. In total, three discordant results were found.
INTRODUCTION
Recently, celiac disease (CD) has markedly changed due to considerable advances in the knowledge of its pathogenic and diagnostic characteristics (1) (2) (3) . CD is now an established immune-mediated systemic disorder elicited by gluten and related prolamines in genetically susceptible individuals. The disease is characterized by the presence of a variable combination of gluten-dependent clinical manifestations, CDspecific antibodies, HLA-DQ2 or HLA-DQ8 haplotypes and enteropathy (4, 5) .
CD is a chronic, multi-organ disease in which small intestinal mucosal damage may lead to malabsorption of nutrients. The only available treatment is a lifelong strict adherence to GFD. The disease may present at any age with a large variety of symptoms and signs (6, 7) . Problems arising from poor absorption can occur in untreated CD, leading to complications ranging from iron deficiency to osteoporosis, infertility and/or cancer. In this sense, early diagnosis is essential to avoid complications.
The prevalence of CD is 1 to 3% in the general population and approximately 10% among first-degree family members of patients with CD (8) . However, only approximately 0.2% is clinically diagnosed (9, 10) . In Spain, the open access for children to general pediatric care, the wide access of physicians to serologic testing and national-level plans for the early detection of CD (11) are factors that could contribute to the observed increase in CD diagnosis.
Current incidence levels of CD are higher than in previous decades due to advances in the understanding of the disease and an increased use of serological techniques. The techniques of serological markers performed are becoming increasingly sensitive and specific, enabling more a precise diagnosis (2) . Although intestinal biopsy is still the diagnostic gold standard, the relevance of serology has recently increased (12). IgA antibodies against tissue transglutaminase (tTG) and endomysium (EmA) are the best markers for CD (4) . The current diagnostic algorithm includes initial serological tests, a genetic susceptibility study and an intestinal biopsy. The ESPGHAN periodically updates the recommendations and clinical guidelines according to the state of the art technical methods and scientific knowledge. The latest ESPGHAN guidelines published in 2012 state that histological assessment may be omitted in symptomatic patients who have high IgA-tTG levels (more than tenfold above the cut-off, > 10 ULN), verified by EmA positivity, and are HLADQ2 and/or HLA-DQ8 heterodimer positive (4).
However, in the majority of cases intestinal biopsy is still considered as the gold standard for the diagnosis of CD.
Deamidated gliadin peptides (DGP) are the most recent family of biomarkers used for the diagnosis of CD (13) (14) (15) (16) (17) (18) (19) . Gliadin is the antigen that triggers the autoimmune reaction of CD and tTG enzymatically deamidates gliadin peptides. This modification of gliadin peptides strengthens the binding to HLADQ2/DQ8 receptors and enhances recognition by T lymphocytes derived from the intestine (20) . Therefore, DGPs are highly specific to the immune reaction involved in the mechanism of CD (21) . In children, the test with anti-DGP antibodies had a greater diagnostic precision than EmA to distinguish CD patients from controls. Moreover, compared with the currently used anti-tTG antibody assays, the DGP-based ELISA test has shown a similar diagnostic precision (22) .
The use of POC testing is an alternative to standard laboratory assays and is an approach which offers fast results and is minimally invasive. In children, a DGP-based POCT showed results which were highly concordant with laboratory tTG testing (23, 24) , including IgA deficient patients (25) . In patients with CD-related symptoms of a wide range of ages (1.8-79.2 years old), the POCT accuracy, sensitivity and specificity was high, especially when only considering the patient subgroup where CD was newly diagnosed (26) . The same POCT performed marginally better than a laboratory IgA anti-tTG assay in determining compliance to GFD in patients with CD (27) . However, not all POCTs are as accurate as conventional laboratory serology, as an IgA tTG-based POCT showed a lower performance than laboratory tTG and EmA tests (28). Therefore, the objective of the present study was to assess the performance of the DGP-based POCT in the early detection of CD in pediatric patients according to the current ESPGHAN criteria.
METHODS
One hundred children under 18 years of age were recruited from the Gastroenterology 
RESULTS
In total, 100 children (49 girls and 51 boys) were included in the study. Age distribution was as follows: 18 were younger than two years of age (16 ± 5 months), 52 were between two and ten years of age (72 ± 27 months), and 30 were older than ten years of age (150 ± 24 months). All patients were referred to the Pediatric Gastroenterology and Nutrition Service due to gastrointestinal symptoms, including diarrhea, nausea and vomiting, poor appetite, cramping, distension and/or abdominal pain. Ten patients had first degree relatives diagnosed with CD and six of them were siblings of celiac patients. Four children presented autoimmune associated diseases (one, type I diabetes; two, thyroiditis; and one, hepatitis). Forty-eight patients were newly diagnosed with CD according to the ESPGHAN criteria (4) resulting in a CD prevalence of 48% in the pediatric cohort.
Forty-seven patients tested positive for IgA-tTG (> 10 AU/I). All of them were further investigated according to the ESPGHAN guidelines. One of the patients (female, ten years of age) with an IgA-tTG value above the cut-off (28 AU/l) showed no villous damage on intestinal biopsy, was CD negative according to the POCT and did not meet ESPGHAN criteria to make a CD diagnosis.
Of the 47 IgA-tTG positive patients, 15 fulfilled the ESPHGAN criteria for biopsy avoidance (4), with high IgA-tTG antibody titters (> 100 AU/l) exceeding ten-times the upper normal limit (> 10 AU/l), genetic results compatible with CD and positive EmA.
These 15 patients (eleven younger than two years of age and four between two and ten years of age) with newly diagnosed CD were all correctly identified using the POCT.
One of the IgA-tTG positive patients had a new diagnosis of the CD-associated autoimmune disease diabetes mellitus type 1 at the time when CD was being testing. However, the POCT was CD negative for this patient and was considered to be a false negative result, as later discussed in the article.
Of the 53 patients who tested negative for IgA-tTG (< 10 AU/I), 28 underwent respectively. A likelihood ratio (LR) was also calculated and a high positive LR of 49.8 (7.2-347.5) and a low negative LR of 0.04 (0.01-0.17) were obtained.
A total of three discordant results were observed using the POCT (Fig. 2 ). There were two false negative POCT results. One patient was a ten year old girl and the sole case All discordant results were obtained from patients over ten years of age. This prompted us to investigate the performance of the POCT in different age groups. In this cohort, 30 patients were older than ten years of age and the POCT yielded three results in this subpopulation that differed from CD diagnosis based on the ESPGHAN criteria. This resulted in a diagnostic accuracy of 90%. However, in the 70 children younger than ten years of age, the POCT had a diagnostic accuracy of 100%. This subgroup included 18 children younger than two years of age and 15 patients that did not require a biopsy according to the ESPHGAN criteria.
DISCUSSION
The advantages of POCT include its minimally invasive and rapid nature, which is particularly important for CD diagnosis in children. Thus, we investigated the accuracy of a DGP-based POCT in pediatric patients referred from Primary Care, secondary care
or private doctors to a specialized Paediatric Gastroenterology service for CD diagnosis. Moreover, this is the first study that compares the results of a CD POCT with the current criteria for CD diagnosis established by the ESPGHAN (4).
The performance of the DGP-based POCT studied here has been previously assessed in paediatric cohorts (23) (24) (25) , but was compared to conventional tTG lab serology and not to diagnostic ESPGHAN criteria. In a large pediatric population and in a second cohort of IgA deficient children, a high negative predictive value was found of 99% and 100%, respectively. The sensitivity values were 93% and 100%, respectively, indicating that this DGP-based POCT allows for accurate CD screening and is a reliable tool to rule out CD in children. Although we used a different reference for the comparison of the POCT results (ESPHGAN criteria), similar negative predictive (96.2%) and sensitivity values (95.8%) were obtained.
Our data suggest that the POCT may be the most accurate method in children younger than ten years of age. However, no similar observation was reported by Bienvenu et al. (23, 25) . Moreover, Kurppa et al. (30) found a high sensitivity for IgA/IgG-DGP antibodies in detecting early-stage CD when the villous morphology has not been affected yet. Despite these positive findings in the literature, further data is needed to validate our hypothesis that the DGP-based POCT is the most suitable for CD diagnosis in children below ten years of age.
In the present study, the use of the ESPGHAN criteria to make a CD diagnosis allowed for a biopsy to be avoided in 15 patients with IgA-tTG levels exceeding the upper normal limit by ten times (> 10 ULN). Of these 15 patients, eleven were younger than two years of age and four were between two and ten years old. All 15 patients were newly diagnosed CD cases, thus IgA-tTG testing was perfectly accurate in this patient subset. Similarly, the POCT based on DGPs correctly identified these 15 patients as CD positive.
Despite the association of CD with the autoimmune disease diabetes mellitus type 1 (31), only one insulin dependent patient was found in this study. Interestingly, this patient was diagnosed with type 1 diabetes during the study period. Peretti et al. (32) suggested that CD is most often present before the onset of diabetes. This is consistent with our findings and justifies the importance of monitoring type I diabetes in CD patients.
It is worth mentioning that the CD prevalence in our study cohort (48%) is higher than that reported in different populations at risk of CD (10). This enrichment of CD patients in our study is due to the fact that subjects were selected from a health service specialized in the detection of gastrointestinal diseases, including CD. Thus, the selection of our patients represents the main limiting factor of our study, since the prevalence of CD found in this sample does not represent the prevalence in the general population.
Our results support the use of this DGP-based POCT in specialized pediatric gastroenterology services. In adult patients, this POCT test demonstrated an equivalent sensitivity of serum tTG and an increased accuracy of the diagnosis of CD when used before endoscopy (33). Further studies are needed to clarify if the POCT could replace conventional laboratory serology in settings where CD prevalence is lower and the risk of celiac disease is higher. However, our results and previous findings show that the POCT is a safe way to achieve a rapid, cost-effective and accurate CD diagnosis. Thus, the selection of our patients represents the limiting factor of our study, since the prevalence of CD found in this sample does not represent the prevalence of the general population.
In conclusion, taking into account its high diagnostic accuracy in the pediatric population and its minimal invasiveness, the POCT used in this study should be considered as an effective tool for the early diagnosis of CD, especially in patients younger than ten years of age. 
